Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here
Thursday, September 29, 2011
Agenix submits manufacturing patent application for hepatitis B drug AGX-1009
The international application aims to provide further long-term protection for the company’s platform hepatitis B drug compounds through until 2030. Agenix already has a registered patent to protect the AGX-1009 compound in China through to 2026. Like Viread, AGX-1009 is a so-called ‘prodrug' of Tenofovir. Gilead’s ‘prodrug’ of Tenofovir was approved for treatment of hepatitis B in the US in 2008 and in numerous countries globally but is not yet approved in China. Both drugs contain Tenofovir but have different molecular side chains to activate that compound. Both drugs work by blocking an enzyme the hepatitis virus needs to replicate.